🇺🇸 FDA
Pipeline program

RYMPHYSIA

TAK-883-4002

Approved mab terminated

Quick answer

RYMPHYSIA for Chronic Obstructive Pulmonary Disease (COPD) is a Approved program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Chronic Obstructive Pulmonary Disease (COPD)
Phase
Approved
Modality
mab
Status
terminated

Clinical trials